Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Assessing response to treatment of exacerbations of bronchiectasis in adults

M. P. Murray, K. Turnbull, S. MacQuarrie, A. T. Hill
European Respiratory Journal 2009 33: 312-318; DOI: 10.1183/09031936.00122508
M. P. Murray
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K. Turnbull
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. MacQuarrie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. T. Hill
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Figures

  • Tables
  • Fig. 1—
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1—

    Changes in clinical markers following 2 weeks of intravenous antibiotic therapy. FEV1: forced expiratory volume in one second, WCC: white cell count; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; SGRQ: St George’s Respiratory Questionnaire.

Tables

  • Figures
  • Table 1—

    Patient characteristics

    Subjects n32
    Male10 (31.3)
    Age yrs62.8±9.8
    Nonsmokers23 (71.9)
    Ex-smokers9 (28.1)
    Ex-smoker pack-yr history34.5±17.2
    COPD3 (9.4)
    Asthma18 (56.3)
    Inhaled corticosteroid therapy28 (87.5)
    Nebulised bronchodilator therapy7 (21.9)
    FEV1 L1.57±0.58
    FEV1 % predicted66.5±27.3
    FVC L2.49±0.78
    FVC % predicted85.3±33.2
    Infective exacerbations in preceding year7.4±6.0
    Number of lobes involved on HRCT4.1±1.7
    Cystic bronchiectasis10 (31.2)
    Chronically colonised29 (90.6)
    • Data are expressed as n (%) or mean±sd, unless otherwise stated. COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; HRCT: high-resolution computed tomography.

  • Table 2—

    Aetiology of bronchiectasis

    Inactive allergic bronchopulmonary aspergillosis11 (34.4)
    Burnt out sarcoidosis1 (3.1)
    Post infective (pneumonia, tuberculosis, pertussis, measles)10 (31.3)
    Ig deficiency (all IgG subclass 2)4 (12.5)
    Ciliary dyskinesia1 (3.1)
    Idiopathic5 (15.6)
    • Data are presented as n (%). Ig: immunoglobulin.

  • Table 3—

    Outcome measures from start to end of exacerbation

    VariableStart of exacerbationEnd of exacerbationp-value
    24-h sputum volume mL30.4±21.98.5±8.4<0.0001
    FEV1 L1.45±0.571.52±0.580.07
    FVC L2.35±0.782.5±0.860.01
    FEV1/FVC61.4±12.360.4±11.50.5
    Exercise capacity m217.0±168.0271±184.0<0.0001
    WCC# x109·L−110.8±7.17.2±2.5<0.0001
    ESR mm·h−140.1±27.422.3±14.1<0.0001
    CRP mg·L−166.9±70.77.4±11.2<0.0001
    • Data are presented as mean±sd, unless otherwise stated. FEV1: forced expiratory volume in one second; FVC: forced vital capacity; WCC: white cell count; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein. #: normal range 4–11×109·L−1.

  • Table 4—

    Individual domain and total St George’s Respiratory Questionnaire scores from start to end of exacerbation

    DomainStart of exacerbationEnd of exacerbationp-value
    Symptoms76.4±12.951.7±23.1<0.0001
    Activity65.5±26.457.4±26.50.01
    Impact47.9±18.437.2±19.2<0.001
    Total score57.9±17.545.7±20.0<0.0001
    • Data are presented as mean±sd, unless otherwise stated.

PreviousNext
Back to top
View this article with LENS
Vol 33 Issue 2 Table of Contents
European Respiratory Journal: 33 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Assessing response to treatment of exacerbations of bronchiectasis in adults
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Assessing response to treatment of exacerbations of bronchiectasis in adults
M. P. Murray, K. Turnbull, S. MacQuarrie, A. T. Hill
European Respiratory Journal Feb 2009, 33 (2) 312-318; DOI: 10.1183/09031936.00122508

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Assessing response to treatment of exacerbations of bronchiectasis in adults
M. P. Murray, K. Turnbull, S. MacQuarrie, A. T. Hill
European Respiratory Journal Feb 2009, 33 (2) 312-318; DOI: 10.1183/09031936.00122508
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • METHODS
    • RESULTS
    • DISCUSSION
    • Support statement
    • Statement of interest
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Prevalence and clinical significance of auto-antibodies in adults with cystic fibrosis
  • A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis
  • Sputum colour: a useful clinical tool in non-cystic fibrosis bronchiectasis
Show more Original Articles: Cystic fibrosis and non-cystic fibrosis bronchiectasis

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society